Univercells
PrivateLast Round
Grant
Oct 9, 2023
Total Funding Raised
$301.34M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Univercells operates in Healthcare & Life Sciences and is based in Charleroi. Its latest recorded funding round was a Grant round in October 2023.
Univercells is a biotechnology company that develops innovative biomanufacturing platforms and services to enhance the accessibility and affordability of vaccines and biotherapeutics.
Sector
Healthcare & Life Sciences
Verticals
Biotech Equipment, Biotechnology
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Univercells Comparables
Compare Univercells with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| OmniBRx Biotechnologies | 85% | |
| Danaher | 78% | |
| Esco Lifesciences Group | 77% |
For institutional investors. Book with your work email.
Univercells Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Oct 9, 2023 | ||||
| Series D | Oct 19, 2022 | ||||
| Debt | Jul 1, 2021 | ||||
| Series C | Dec 17, 2020 | ||||
| Corporate Funding | Feb 18, 2020 | ||||
Debt | Oct 3, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Univercells Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Federal Holding and Investment Company | Series C, Series D |
| Farallon Capital Management | Series C |
| Kohlberg Kravis Roberts | Corporate Funding |
| Korea Investment Partners | Series C, Series B |
| The Innovation Fund | Series B |
| Gamma Biosciences | Corporate Funding |
| Société Régionale d'Investissement de Wallonie | Series C, Series D |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 27, 2026
Monthly visitors increased 1261% MoM, from 38 to 517.
- Oct 9, 2023
$20M raised from Gates Foundation.
For institutional investors. Book with your work email.
Univercells Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Univercells's valuation, stock price, and market status.
Is Univercells a public or private company?
Univercells is a private company.
What is the current stock price of Univercells?
Univercells is a private company, so its shares have no public market price. Caplight tracks Univercells's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Univercells worth (valuation)?
Valuation information for Univercells is not publicly available.
Can I buy Univercells stock?
Univercells shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Univercells's last funding round?
Univercells's most recent funding round was Grant on October 9, 2023.
Who are the main investors in Univercells?
Key investors in Univercells include Federal Holding and Investment Company, Farallon Capital Management, Kohlberg Kravis Roberts, Gamma Biosciences, Société Régionale d'Investissement de Wallonie.
Will Univercells IPO soon?
No public IPO plans have been announced for Univercells.
How can I track Univercells secondary market activity?
Caplight tracks bids, offers, and trades in Univercells's shares on secondary markets.